Molecular Imaging is Impacting the Current Cancer Treatment

時間地點:10:30 am, Nov 28 (Mon), 2022; R1-B1122 Conference Room

研討講者:Ching-Hsuan Tung, Ph.D.

November 09, 2022


Over the past two decades, a few FDA approved molecular imaging probes, which report biological abnormity of cancerous tissue, have played critical roles in cancer management. For example, 18F-FDG PET/CT imaging is widely used to detect tumor, trace metastasis, and evaluate therapeutic outcome. Although the number of approved molecular imaging probes is still low, many promising candidates are on the horizon. These novel probes are specifically designed, based on various mechanisms, to image cancer-associated biomarkers, metabolites, enzymatic activity, and microenvironment. Their imaging signals acquired non-invasively reflect the status of the target-of-interests in the native tumor microenvironment in whole body. The gathered real-time biological information, which is not available in the past, is expected to revolutionize the current treatment strategies. This seminar will briefly introduce the existing and potential applications of molecular imaging in tumor detection, treatment planning, treatment evaluation, real time surgical guidance and drug development. The obstacles of translating these unconventional molecular imaging probes into clinical practice will also be discussed.

Ching-Hsuan Tung, Ph.D.

Molecular Imaging Innovations Institute

Weill Cornell Medical College, New York.

Ching-Hsuan Tung, Ph.D.

Molecular Imaging Innovations Institute,
Department of Radiology,
Weill Cornell Medical College, New York.

1987-1992   Ph.D.  Chemistry Rutgers — The State University of New Jersey New Brunswick, New Jersey, USA
1979-1983   B.S.   Chemistry National Cheng Kung University, Tainan, Taiwan

Professional Experience
2008 - Present  Professor of Chemistry in Radiology, Molecular Imaging Innovations Institute, Department                                               of Radiology, Weill Cornell Medical College, New York.
2013 - 2022  Alexander R. Margulis MD Distinguished Professor in Radiology, Weill Cornell Medical                                                     College, New York.
2013 - 2020  Founding Director, Molecular Imaging Innovations Institute, Department of Radiology.
1998 - 2007  Assistant and Associate Professor of Chemistry in Radiology, Center for Molecular Imaging                                             Research, Department of Radiology, Massachusetts General Hospital, Harvard Medical School,                                       Boston, MA.

學術論文:> 170篇,
Citations  : > 15,000, h-index 62, Scopus

Awards and Honor
2019-present     World's top 2% scientists (for career-long)
2018             Fellow, American Institute for Medical and Biological Engineering
2015             Distinguished Investigator, Academy of Radiology Research
2014             Plenary Speaker, 8th National Cancer Center International Symposium, Seoul, Korea
2010             Adjunct Professor, Health Science Division, Monterrey Institute of Technology, Mexico
2009             20 Most-Prolific Authors, Bioconjugate Chemistry
2009             Scientific steering committee, NIH Imaging Probes Development Center
2008             Adjunct Associate Professor of Bioengineering, Rice University, Houston, Texas
2006             Plenary Speaker, Annual meeting of Radiology Society, Taiwan
2000             CaP CURE research award
1998             RSNA seed grant award